Inactive Instrument

Press Releases Aimmune Therapeutics, Inc.

Equities

AIMT

US00900T1079

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU	21-01-22	AQ
Aimmune Therapeutics : European Commission approves first treatment for peanut allergy	21-01-05	AQ
Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU	20-12-22	AQ
Aimmune Therapeutics : European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU	20-12-21	BU
AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers (form 8-K)	20-10-19	AQ
Aimmune Therapeutics : Receives Positive CHMP Opinion on PALFORZIA for the Treatment of Patients with Peanut Allergy in Europe	20-10-19	AQ
Aimmune Therapeutics : Nestle Completes Acquisition of Aimmune Therapeutics	20-10-15	AQ
Aimmune Therapeutics : Nestle announces results of tender offer for Aimmune Therapeutics Inc.	20-10-13	AQ
Aimmune Therapeutics : Nestle commences tender offer for Aimmune Therapeutics Inc	20-09-15	AQ
Aimmune Therapeutics : Nestlé commences tender offer for Aimmune Therapeutics, Inc.	20-09-14	PR
AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aimmune Therapeutics Inc. - AIMT	20-09-04	BU
Aimmune Therapeutics : Nestle to acquire Aimmune Therapeutics	20-09-01	AQ
Aimmune Therapeutics : Nestlé Health Science to acquire Aimmune Therapeutics for $2.6 billion	20-09-01	AQ
Aimmune Therapeutics : Enters Definitive Agreement with Societes des Produits Nestle S.A. Part of Nestle Health Science	20-09-01	AQ
WeissLaw LLP Investigates Aimmune Therapeutics, Inc.	20-08-31	PR
Yum China : Aimmune rise; Regis, Walmart fall	20-08-31	AQ
AIMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	20-08-31	AQ
Aimmune Therapeutics : Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science	20-08-31	BU
Aimmune Therapeutics : Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions	20-08-25	AQ
Aimmune Therapeutics : Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers	20-08-24	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aimmune Therapeutics, Inc.

Equities

AIMT

US00900T1079

Press Releases

Filters